BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 247 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q4 2020. The put-call ratio across all filers is 0.72 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $1,300,000 | -86.2% | 8,600 | -86.7% | 0.01% | -85.2% |
Q2 2022 | $9,413,000 | -71.5% | 64,600 | -76.8% | 0.06% | -66.8% |
Q1 2022 | $33,034,000 | -16.5% | 278,600 | -3.0% | 0.18% | -5.6% |
Q4 2021 | $39,565,000 | +2.6% | 287,100 | +3.4% | 0.20% | -3.5% |
Q3 2021 | $38,561,000 | +35.7% | 277,600 | -5.1% | 0.20% | +36.5% |
Q2 2021 | $28,406,000 | +55.3% | 292,600 | +9.3% | 0.15% | +42.3% |
Q1 2021 | $18,290,000 | -8.3% | 267,600 | +15.0% | 0.10% | -14.0% |
Q4 2020 | $19,936,000 | +13.8% | 232,600 | -13.7% | 0.12% | -5.5% |
Q3 2020 | $17,520,000 | -51.0% | 269,500 | -44.8% | 0.13% | -15.8% |
Q2 2020 | $35,722,000 | +325.0% | 488,600 | +97.8% | 0.15% | -16.0% |
Q1 2020 | $8,405,000 | -39.9% | 247,000 | -3.9% | 0.18% | -25.2% |
Q4 2019 | $13,991,000 | +44.6% | 257,000 | +10.8% | 0.24% | +23.5% |
Q3 2019 | $9,679,000 | +45.4% | 232,000 | +52.6% | 0.20% | +59.3% |
Q2 2019 | $6,656,000 | – | 152,000 | – | 0.12% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 1,111,111 | $107,867,000 | 52.60% |
Knoll Capital Management, LLC | 856,844 | $83,182,000 | 43.44% |
ORACLE INVESTMENT MANAGEMENT INC | 2,082,555 | $202,174,000 | 27.86% |
ARS Investment Partners, LLC | 558,286 | $54,198,000 | 5.52% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $17,113,000 | 4.52% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 401,006 | $38,930,000 | 4.51% |
Eventide Asset Management | 1,990,797 | $193,267,000 | 2.60% |
SILVERARC CAPITAL MANAGEMENT, LLC | 56,626 | $5,497,000 | 2.45% |
Avidity Partners Management LP | 882,500 | $85,673,000 | 2.32% |
Nicholas Investment Partners, LP | 363,708 | $35,309,000 | 2.22% |